LobSor Pharmaceuticals and TFS report LECIGon® Achieving Its Primary Endpoint in a Pivotal EU Study for Advanced Parkinson’s Disease
· LobSor plans to submit its regulatory application for EU approval in early 2016 · LobSor in process of planning discussions with the U.S. Food and Drug Administration (FDA) to outline US path to commercialization LobSor Pharmaceuticals, a specialty pharmaceutical company based in Sweden, announced that LECIGon® has achieved its primary endpoint in a late-stage study examining the pharmacokinetics of LECIGon® compared to Abbvie’s Duodopa® in the treatment of advanced Parkinson’s disease. When comparing the levodopa bioavailability during daytime enteral infusion, LECIGon demonstrated